Ranbaxy Laboratories Ltd (RANB.BO)

RANB.BO on Bombay Stock Exchange

623.75INR
3:50pm IST
Price Change (% chg)

Rs1.60 (+0.26%)
Prev Close
Rs622.15
Open
Rs622.15
Day's High
Rs632.00
Day's Low
Rs620.00
Volume
107,802
Avg. Vol
144,924
52-wk High
Rs667.30
52-wk Low
Rs306.05

RANB.BO

Chart for RANB.BO

About

Ranbaxy Laboratories Limited is an integrated international pharmaceuticals company. The Company is engaged in the marketing, production and distribution of pharmaceutical products. The Company’s business activity falls within a single primary business segment viz. Pharmaceutical. The Company has ground operations in over 40... (more)

Overall

Beta: 0.65
Market Cap (Mil.): Rs264,657.50
Shares Outstanding (Mil.): 424.57
Dividend: --
Yield (%): --

Financials

  RANB.BO Industry Sector
P/E (TTM): -- 33.49 34.41
EPS (TTM): -20.63 -- --
ROI: -- 18.10 17.37
ROE: -- 18.76 18.18
Search Stocks

Indian drugmaker Ranbaxy still has exclusive rights for Nexium generic: CEO

MUMBAI - Indian drugmaker Ranbaxy Laboratories still has exclusive rights to the launch of AstraZeneca's heartburn drug Nexium in the United States, it said on Tuesday, despite regulatory concern over the manufacturing process.

28 Oct 2014

Ranbaxy still has exclusive rights for Nexium generic - CEO

MUMBAI - Ranbaxy Laboratories still has exclusive rights to the launch of AstraZeneca's heartburn drug Nexium in the United States, it said on Tuesday, despite regulatory concern over the manufacturing process.

28 Oct 2014

Indian drugmaker Ranbaxy still has exclusive rights for Nexium generic -CEO

MUMBAI, Oct 28 - Indian drugmaker Ranbaxy Laboratories still has exclusive rights to the launch of AstraZeneca's heartburn drug Nexium in the United States, it said on Tuesday, despite regulatory concern over the manufacturing process.

28 Oct 2014

Indian shares climb to one-month closing high; Ranbaxy up after profit

* BSE index gains 0.48 pct; NSE ends 0.45 pct higher * Banks lead on continued rate-cut hopes * Jubilant Foodworks falls ahead of earnings By Abhishek Vishnoi MUMBAI, Oct 28 - Indian shares rose on Tuesday to their highest close in more than a month, with drugmakers getting a shot in the arm after Ranbaxy Laboratories Ltd reported its first profit in six quarters. Lenders also extended recent gains on rising expectations the Reserve Bank of India would cut rates e

28 Oct 2014

Ranbaxy books first profit in six quarters on exclusive drug launch

MUMBAI - Generic drugmaker Ranbaxy Laboratories Ltd on Tuesday reported its first profit in six quarters after benefiting from the exclusive U.S. launch of a cheaper copy of Novartis AG blood pressure pill Diovan.

28 Oct 2014

UPDATE 1-India's Ranbaxy books first profit in 6 quarters on exclusive drug launch

* Shares rise 6 pct, outpacing market (Adds details on results, shares, context)

28 Oct 2014

Ranbaxy surges after profit, Sun Pharma also gains

Reuters Market Eye - Ranbaxy Laboratories gains 4.5 percent. Sun Pharmaceutical Industries , which is in the process of acquiring Ranbaxy, also jumps 4.4 percent.

28 Oct 2014

MARKET EYE -India's Ranbaxy surges after profit, Sun Pharma also gains

* Ranbaxy Laboratories gains 4.5 percent. * Sun Pharmaceutical Industries, which is in the process of acquiring Ranbaxy, also jumps 4.4 percent. * Ranbaxy posts a profit of 4.78 billion rupees ($78 million), compared with a loss of 4.5 billion rupees a year earlier. * The company's earnings got a boost from the launch of generic Valsartan in the U.S. with 180 days exclusivity - Analysts. * Valsartan is a cheaper copy of Novartis AG's blood pressure pill Diovan. * The Indian pharma index gaine

28 Oct 2014

India's Ranbaxy posts Q2 profit

MUMBAI, Oct 28 - Indian generic drugmaker Ranbaxy Laboratories Ltd, which is in the process of being acquired by larger rival Sun Pharmaceutical Industries Ltd , reported a profit in its second quarter.

28 Oct 2014

INDIA PRESS-Ranbaxy may lose heartburn drug Nexium exclusivity - Business Standard

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aditya Kondalamahanty in Bangalore)

27 Oct 2014

Earnings vs. Estimates

Search Stocks